Gene therapy to the rescue in Parkinson's disease. Response from Kordower and Aebischer.
Research Center for Brain Repair and Dept of Neurological Sciences, Rush Presbyterian Medical Center, 60612,., Chicago, IL, USA
J H
JH
Kordower
P
P
Aebischer
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D015259:Dopamine Agents / Q000009:adverse effects; D015316:Genetic Therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor; D000882:Haplorhini; D006801:Humans; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000628:therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced
D015259:Dopamine Agents; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine